Purple Biotech Ltd. Updates Corporate Presentation
Ticker: PPBT · Form: 6-K · Filed: Nov 19, 2025 · CIK: 1614744
Sentiment: neutral
Topics: corporate-update, presentation, foreign-private-issuer
TL;DR
Purple Biotech dropped a new investor deck on 11/19/25.
AI Summary
On November 19, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate Presentation November 2025". This filing is a Report of Foreign Private Issuer under the Securities Exchange Act of 1934.
Why It Matters
This update provides current information to investors and stakeholders about the company's progress and strategy.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain significant financial or operational news.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the report
- November 19, 2025 (date) — Date of the corporate presentation release
- Exhibit 99.1 (document) — The attached corporate presentation
FAQ
What is the purpose of this 6-K filing?
This 6-K filing serves as a Report of Foreign Private Issuer, primarily to attach an updated corporate presentation released by Purple Biotech Ltd.
What is the title of the updated presentation?
The updated presentation is titled "Purple Biotech Corporate Presentation November 2025".
When was the updated corporate presentation issued?
The updated corporate presentation was issued on November 19, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
What is the SIC code for Purple Biotech Ltd.?
The Standard Industrial Classification (SIC) code for Purple Biotech Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 183 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-11-19 17:07:28
Filing Documents
- ea0266474-6k_purple.htm (6-K) — 9KB
- ea026647401ex99-1_purple.htm (EX-99.1) — 77KB
- ex99-1_001.jpg (GRAPHIC) — 813KB
- ex99-1_002.jpg (GRAPHIC) — 1417KB
- ex99-1_003.jpg (GRAPHIC) — 739KB
- ex99-1_004.jpg (GRAPHIC) — 513KB
- ex99-1_005.jpg (GRAPHIC) — 519KB
- ex99-1_006.jpg (GRAPHIC) — 768KB
- ex99-1_007.jpg (GRAPHIC) — 884KB
- ex99-1_008.jpg (GRAPHIC) — 549KB
- ex99-1_009.jpg (GRAPHIC) — 555KB
- ex99-1_010.jpg (GRAPHIC) — 592KB
- ex99-1_011.jpg (GRAPHIC) — 617KB
- ex99-1_012.jpg (GRAPHIC) — 797KB
- ex99-1_013.jpg (GRAPHIC) — 797KB
- ex99-1_014.jpg (GRAPHIC) — 834KB
- ex99-1_015.jpg (GRAPHIC) — 456KB
- ex99-1_016.jpg (GRAPHIC) — 631KB
- ex99-1_017.jpg (GRAPHIC) — 715KB
- ex99-1_018.jpg (GRAPHIC) — 826KB
- ex99-1_019.jpg (GRAPHIC) — 712KB
- ex99-1_020.jpg (GRAPHIC) — 834KB
- ex99-1_021.jpg (GRAPHIC) — 777KB
- ex99-1_022.jpg (GRAPHIC) — 693KB
- ex99-1_023.jpg (GRAPHIC) — 616KB
- ex99-1_024.jpg (GRAPHIC) — 615KB
- ex99-1_025.jpg (GRAPHIC) — 581KB
- ex99-1_026.jpg (GRAPHIC) — 566KB
- ex99-1_027.jpg (GRAPHIC) — 608KB
- ex99-1_028.jpg (GRAPHIC) — 581KB
- ex99-1_029.jpg (GRAPHIC) — 665KB
- ex99-1_030.jpg (GRAPHIC) — 794KB
- ex99-1_031.jpg (GRAPHIC) — 694KB
- ex99-1_032.jpg (GRAPHIC) — 780KB
- ex99-1_033.jpg (GRAPHIC) — 359KB
- ex99-1_034.jpg (GRAPHIC) — 740KB
- ex99-1_035.jpg (GRAPHIC) — 460KB
- ex99-1_036.jpg (GRAPHIC) — 702KB
- ex99-1_037.jpg (GRAPHIC) — 378KB
- ex99-1_038.jpg (GRAPHIC) — 572KB
- ex99-1_039.jpg (GRAPHIC) — 455KB
- ex99-1_040.jpg (GRAPHIC) — 609KB
- ex99-1_041.jpg (GRAPHIC) — 520KB
- ex99-1_042.jpg (GRAPHIC) — 569KB
- ex99-1_043.jpg (GRAPHIC) — 606KB
- ex99-1_044.jpg (GRAPHIC) — 723KB
- ex99-1_045.jpg (GRAPHIC) — 635KB
- ex99-1_046.jpg (GRAPHIC) — 651KB
- ex99-1_047.jpg (GRAPHIC) — 254KB
- ex99-1_048.jpg (GRAPHIC) — 837KB
- ex99-1_049.jpg (GRAPHIC) — 421KB
- ex99-1_050.jpg (GRAPHIC) — 681KB
- ex99-1_051.jpg (GRAPHIC) — 597KB
- ex99-1_052.jpg (GRAPHIC) — 654KB
- ex99-1_053.jpg (GRAPHIC) — 711KB
- ex99-1_054.jpg (GRAPHIC) — 750KB
- ex99-1_055.jpg (GRAPHIC) — 418KB
- ex99-1_056.jpg (GRAPHIC) — 853KB
- ex99-1_057.jpg (GRAPHIC) — 710KB
- 0001213900-25-112706.txt ( ) — 51602KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. November 19, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2